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PENENTUAN NILAI AMBANG KOS BERKESAN DI MALAYSIA 
 
ABSTRAK 
 
Dalam sistem penjagaan kesihatan, penentuan untuk kos berkesan bagi teknologi 
penjagaan kesihatan adalah sukar terutamanya dalam keadaan di mana terdapat 
alternatif-alternatif yang lebih mahal tetapi lebih berkesan. Dalam keadaan ini, satu 
kriteria luaran dalam bentuk nilai ambang kos berkesan ataupun WTP/QALY diperlukan 
untuk menentukan kos keberkesanan intervensi penjagaan kesihatan. Namun, amalan 
kini di Malaysia dalam penentuan kos keberkesanan untuk teknologi penjagaan 
kesihatan baru dilakukan tanpa satu nilai ambang kos berkesan yang jelas. Jadi, tujuan 
utama kajian ini adalah untuk menentukan nilai ambang kos berkesan bagi intervensi 
penjagaan kesihatan di Malaysia. Satu kajian cross-sectional, penilaian kontingen telah 
dijalankan dengan menggunakan teknik persampelan rawak kelompok berstrata di Pulau 
Pinang, Kedah, Selangor dan Wilayah Persekutuan Kuala Lumpur. Responden berumur 
antara 20 – 60 tahun yang memahami sama ada Bahasa Inggeris atau Bahasa Melayu 
ditemuduga secara bersemuka. Mereka ditanya tentang latar belakang sosio-ekonomik, 
mutu kehidupan dan kesanggupan untuk membayar satu senario hipotetikal (rawatan, 
lanjutan nyawa dalam penyakit terminal dan situasi penyelamatan nyawa dengan tiga 
tahap keterukan penyakit dan dua tahap QALY – 0.2 QALY dan 0.4 QALY). Nisbah 
purata nilai WTP bagi satu QALY diterokai dengan menggunakan kaedah bukan 
parametrik Turnbull dan model parametrik interval regression. Model parametrik 
interval regression juga digunakan untuk menganalisa faktor-faktor yang mempengaruhi 
nilai ambang kos berkesan. Seribu tiga belas responden telah ditemuduga semasa kaji 
xviii 
 
selidik dijalankan. Nilai ambang kos berkesan yang diterokai dari kaedah bukan 
parametrik Turnbull ialah antara Ringgit Malaysia 12,810 – 22,840 (~ Dolar Amerika 
Syarikat 4,000 – 7,000) manakala nilai ini dianggar antara Ringgit Malaysia 19,929 – 
28,470 (~ Dolar Amerika Syarikat 6,200 – 8,900) dengan menggunakan model 
parametrik interval regression. Faktor-faktor utama yang mempengaruhi nilai ambang 
kos berkesan ialah tahap pendidikan, anggaran pendapatan bulanan isi rumah dan 
penerangan senario keadaan kesihatan. Nilai ambang kos berkesan yang didapati dalam 
kajian ini ialah antara Ringgit Malaysia 19,929 – 28,470. Keputusan yang diperoleh 
menyokong bahawa nilai QALY tidak boleh dirujuk sebagai satu nilai tunggal. Nilai 
ambang kos berkesan yang dianggar untuk Malaysia adalah didapati lebih rendah 
daripada nilai ambang kos berkesan dengan satu hingga tiga kali keluaran dalam negara 
kasar per kapita yang disyorkan oleh pertubuhan kesihatan sedunia.  
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DETERMINATION OF COST-EFFECTIVENESS THRESHOLD FOR 
MALAYSIA 
 
ABSTRACT 
 
In healthcare system, decisions on the cost-effectiveness (CE) of healthcare technologies 
are difficult especially when alternatives are more expensive but more effective. In this 
situation, an external criterion in the form of CE threshold or willingness-to-pay for a 
quality-adjusted life-year (WTP/QALY) is necessary to decide on the CE of healthcare 
interventions. Nevertheless, current practice in Malaysia on coverage decisions of new 
healthcare technologies is made without an explicit CE threshold. Thus, this study aimed 
to determine a CE threshold value for healthcare interventions in Malaysia. A cross-
sectional, contingent valuation study was conducted using stratified multistage cluster 
random sampling technique in Penang, Kedah, Selangor and Kuala Lumpur Federal 
Territory. Respondents aged between 20 – 60 years old who can understand either 
English or Malay language were interviewed face-to-face. They were asked for the 
socioeconomic background, quality of life and their WTP for a hypothetical scenario 
(treatment, extended life in terminal illness and life saving situations with three 
severities and two QALY gained levels – 0.2 QALY and 0.4 QALY). The mean ratio of 
the amount of WTP for an additional QALY gained was explored by non-parametric 
Turnbull method and parametric interval regression model. Parametric interval 
regression model was also used to analyse the factors that affect the CE threshold. One 
thousand thirteen respondents were interviewed during the survey. The CE threshold 
explored from non-parametric Turnbull method ranged from MYR 12,810 – 22,840 (~ 
xx 
 
USD 4,000 – 7,000) whereas it was estimated to range between MYR 19,929 – 28,470 
(~ USD 6,200 – 8,900) using parametric interval regression model. Key factors that 
affect the CE threshold were education level, estimated monthly household income and 
the description of health state scenarios.   
The cost-effectiveness threshold found in this study was reported as MYR 19,929 – 
28,470. The findings support that there is no single value of a QALY. The CE threshold 
estimated for Malaysia was found to be lower than the threshold value of one to three 
times the gross domestic product per capita recommended by the World Health 
Organisation. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 The Importance of Economic Evaluation in Healthcare 
Economic is defined as a study on how men and society end up choosing, with or 
without the use of money, to employ scarce productive resources that could have 
alternative uses, to produce various commodities and distribute them for consumption, 
now or in the future, among various people and groups in society. It analyses the costs 
and benefits of improving patterns of resource allocation (Sameulson and Nordhaus, 
1998, Shiell et al., 2002). 
 For a long time, it is noted that health expenditures have been seen rising far 
more rapidly than the national income generated in most countries. In response, many 
countries are having dilemma in getting sufficient funds to ensure universal access to all 
health interventions and services (Chisholm and Evans, 2007). Under the situation of 
limited budget and the pervasive scarcity of resources available to supply health 
demands, economic considerations are getting an increasingly prominent role in the 
evaluation of healthcare interventions.  
 Economic evaluation, is an economic tool that can be usefully employed to 
address the question of how to achieve the highest possible overall level of population 
health for the available resources (Chisholm and Evans, 2007). In this context, the basic 
task of economic evaluation is to identify, measure, value, and compare the costs and 
consequences of the alternatives being considered which in turn is crucial to provide 
information for policymakers in determining the best forgone choice between the 
competing alternatives (Berger et al., 2003, Drummond et al., 2005). Decision making 
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in health is inherently value-laden, where policymakers need sound evidence of the 
likely costs and benefits of their decisions, articulated through a prism of societal values. 
A good decision making in healthcare setting should always consider the additional 
costs of an intervention as well as the health consequences of those additional costs that 
are reflected from the perspective of individual patient level to a societal level. 
Economic evaluation serves as a robust methodology for determining the costs and 
benefits of an intervention (NICE International, 2014).  
 
1.2 Basic Concept of Economic Evaluation  
Economic evaluation is defined as the comparative analysis of alternative courses of 
action in terms of both their costs and consequences (Drummond et al., 2005). However, 
there are also some cases where the evaluations deal only with the analysis of either 
costs or consequences of the competing alternatives. Some even deal with the analysis of 
cost and consequence within a single programme without comparing to other 
alternatives. In these cases, they are classified as partial economic evaluation. In full 
economic evaluation, both the costs and consequences of the alternatives are examined. 
Three major analytic techniques are commonly used in healthcare. They are cost-benefit 
analysis (CBA), cost-effectiveness analysis (CEA), and cost-utility analysis (CUA). All 
these three types of analyses are similar in how they measure costs but differing in the 
way that the consequences of healthcare programmes are measured and valued 
(Drummond et al., 2005). 
 CBA is a form of economic evaluation that enumerates and compares the net 
costs of a healthcare intervention with the benefits that arise as a consequence of 
applying that intervention. Both the net costs and the consequences of the health 
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intervention are expressed in a commensurate unit, often money (Shiell et al., 2002, 
Berger et al., 2003).  
 CEA is also a form of full economic evaluation that compares both the costs and 
consequences of health care programmes, where the consequences of the programmes 
are measured in the same common units – natural units related to the clinical objective 
of the programmes, such as life-years gained, points of blood pressure reduction and so 
on (Berger et al., 2003). The outcomes in CEA are single, programme specific, and 
unvalued. Typically the results are expressed as cost per effectiveness ratio (Drummond 
et al., 2005).  
 The final analytical technique, CUA, is another form of economic evaluation 
which has a lot of similarities to CEA except for the outcomes that are measured in the 
units of utility or preference, often quality-adjusted life-year (QALY) gained, or possibly 
some variant, like disability-adjusted life-year (DALY) or healthy year equivalent (HYE) 
(Shiell et al., 2002, Berger et al., 2003, Drummond et al., 2005). Unlike CEA, the 
outcomes in CUA may be single or multiple, are generic as opposed to programme 
specific, and incorporate the notion of value. In CUA, the results are normally presented 
in the terms of cost per QALY gained (Drummond et al., 2005). 
 
1.2.1 Moving Towards Cost-Utility Analysis  
CEA is unequivocally the most widely used technique of economic evaluation in the 
field of health economics. Nevertheless, CUA has increasingly become more popular 
and its application has been extended to a wide variety of health interventions including 
pharmaceuticals, surgical procedures and diagnostic imaging (Neumann et al., 2005, 
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Fang et al., 2011). The steady growth of CUA is due to its credibility in overcoming few 
problems faced when using CEA as a technique in economic evaluation.  
 First, the outcomes measured in CEA are programme-specific units such as 
millimetres mercury of blood pressure reduction, cases prevented, life-years gained and 
so on where different programmes may be designated with different outcome units. In 
such a condition, CEA can only be used to compare alternatives with similar outcome 
units but cannot be used to make comparisons across a broad set of interventions with 
different outcome units (Drummond et al., 2005). In order to be able to compare the 
different options for the use of common resources, the quantification of health outcomes 
using a common measurement unit is necessary. CUA was therefore developed to 
address this shortage. It provides a method through which the various disparate 
outcomes can be combined into a single composite summary outcome (e.g. QALY 
gained), which in turn, enable broad comparisons across widely differing programmes 
(Drummond et al., 2005, Dernovsek et al., 2007). 
 Second, CEA cannot address the issue of opportunity cost of funding the new 
programme whereas CUA on the other hand is able to do so (Drummond et al., 2005). 
The standard outcomes measurement of cost per QALY gained in CUA allows one to 
determine a level of ‘acceptable’ cost utility for health care choices: that is, a ‘threshold 
level’ of cost per QALY (Berger et al., 2003). Third, in any one programme there is 
usually more than one outcome of interest. In CEA, the outcomes presented are single, 
programme-specific and cannot be valued. On the contrary, the outcomes in CUA may 
be single or multiple, are generic as opposed to programme specific, and there are values 
attached to the outcomes where the more important outcomes are weighted more heavily 
(Drummond et al., 2005). 
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 In addition, CUA has the advantage over other cost-effectiveness methodologies 
because it incorporates quality of life measure. Health related quality of life (HRQoL) 
represents a crucial measure of therapeutic effectiveness especially when two 
alternatives differ in their effect on quality of life as well as survival and it has become 
an important element in the economic evaluation. CUA is an adaptation of CEA which 
measures the effect of treatment on both the quantitative (length of life or mortality) and 
qualitative (quality of life or morbidity) aspect of health (Berger et al., 2003, Dernovsek 
et al., 2007). CUA is now becoming more common and can be considered as the “gold 
standard” methodology among other cost-effectiveness techniques (Berger et al., 2003). 
Therefore, many health authorities worldwide and experts in the field of health 
economics and outcomes research have recommended the use of CUA in evaluating the 
cost-effectiveness of the health care programmes (Fang et al., 2011). 
 
1.2.2 The concept of Quality-adjusted Life-year 
Many cost-effectiveness (or clinical) studies express health outcomes in term of 
programme-specific measures such as number of cases avoided or life year gained 
without taking into the consideration of quality adjustment. Although these measures are 
useful in comparing the effects of particular treatment but they do not permit the 
comparison across widely differing diseases or programmes. For this reason, the concept 
of QALY has been introduced as a convenient metric for such purposes (Neumann and 
Greenberg, 2009, Smith et al., 2009).  
 QALY is a universal health outcome measure used in CUA which is able to 
capture simultaneously both the changes in quantity of life (mortality) and the changes 
in quality of life (morbidity), and integrate these into a single measure. It is applicable to 
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all individuals and all diseases, thereby enabling broad comparisons across differing 
programmes or diseases (Berger et al., 2003, Smith et al., 2009).  
 QALYs are the life years adjusted by a preference-based quality weight (health-
related quality of life). The quality weights for QALYs must be based on preferences, 
anchored on perfect health with a score of 1.0 and being dead has a score of 0.0, and 
measured on an interval scale. In order to qualify as preference-based instrument, the 
quality weights must represent the preferences of individuals for the relevant health 
states as measured with appropriate preference measurement instruments such as 
standard gambling, time trade-off, Health Utilities Index, EuroQoL EQ-5D, quality of 
well-being instrument or visual analogue scale (VAS). The more desirable (or more 
preferred) health states receive greater weight and will be favoured in the analysis 
compared to those that are worse or less desirable. The preference exist in QALY 
satisfies the von Neumann-Morgenstern axioms where an individual should be 
indifferent between two risky prospects (Berger et al., 2003, Drummond et al., 2005, 
Neumann and Greenberg, 2009).  
 The scale of QALY weights must contain two anchor points on the interval scale 
– perfect health and death. These two points can be given any two arbitrary values as 
long as death has a smaller value than perfect health. For instance, a value of zero may 
represent death while perfect health may be represented by a value of one. In fact, there 
is no well-defined upper end or bottom of the scale. Nevertheless, the pair of values zero 
and one is conventionally assigned to represent death and perfect health respectively in 
the scale of QALY weights (Drummond et al., 2005). 
 The QALY value is calculated by the product of the survival time in a particular 
health state and its quality-adjustment weight (the utility value) (Drummond et al., 2005). 
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As illustrated in Figure 1.1 (Torrance, 1996), without intervention, an individual’s 
HRQoL would deteriorate according to the lower path and the person would die at time 
Death 1. With the intervention, the individual would live longer with the HRQoL 
deteriorate more slowly and would die at time Death 2. The area between the two curves 
is the QALY gained by the intervention. From the diagram shown, Part A is the amount 
of QALY gained due to quality improvement (the gain in health related quality of life) 
and Part B is the amount of QALY gained due to quantity improvement (the amount of 
life extension). Simply taking, QALY is calculated by the area under the curve, where 
the duration of the health state in years is multiplied by the quality weight for the health 
state. (Berger et al., 2003, Drummond et al., 2005). 
 
 
Figure 1.1: Quality-adjusted Life-years Gained from an Intervention 
Source: Adapted from Torrance, 1996 
 
 The concept of QALY has been used universally but is not without controversy. 
Arguments ranged from those questioning that the QALY approach is needlessly 
complex and should be replaced by simpler disaggregated measures to those who think 
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that the QALY concept is overly simplistic and should be replaced by more complex 
methods (Mehrez and Gafni, 1989, Mehrez and Gafni, 1992). Several alternatives to 
QALY have therefore been suggested. For example, the World Bank uses DALY and 
others suggest the use of HYE and saved-young-life equivalent (SAVE) (Berger et al., 
2003, Drummond et al., 2005).  
 Conceptually, the DALY approach is similar to QALY approach but an 
important difference between them is that DALY uses an age-weighting function that 
values life years differently depending on the age of disease onset (Whitehead and Ali, 
2010). The value choices built into the DALY (the age weight, the discount rate and the 
disability weights) have a major influence on the rankings of programmes, and yet these 
value choices are arbitrary and are far from transparency (Drummond et al., 2005). For 
HYE, it truly reflects a person’s utility function over the lifetime through the 
measurement of the preferences over the entire path of health states rather than a single 
health state in QALY approach. In such a condition, it is theoretical attractive but more 
difficult to be implemented in practice (Drummond et al., 2005, Whitehead and Ali, 
2010). Compared to QALY approach, the SAVE approach is less willing to take 
mortality risks to improve quality of life because it appears to give more emphasis to 
quantity of life, and less to quality of life (Drummond et al., 2005). 
 As an overall comparison, the lack of a simple better measure as an alternative 
makes the QALY an indispensable tool (Smith et al., 2009). The QALY approach 
provides an imperfect but nonetheless useful proxy as a measure of value to inform 
reimbursement decisions in healthcare and most cost-utility analyses (CUAs) are 
conducted using cost per QALY as the unit of measurement (Berger et al., 2003, 
Neumann and Greenberg, 2009).  
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1.2.3  Incremental Cost-effectiveness Ratio 
In both CEA and CUA, the results are usually expressed in the terms of incremental 
cost-effectiveness ratio (ICER). ICER is a ratio calculated by dividing the difference in 
cost (incremental cost) between two alternatives to the difference in effects (incremental 
effects) of these two alternatives (Berger et al., 2003). The formula for the calculation of 
ICER is shown below: 
                          ICER =    Cost of Programme A – Cost of Programme B 
                                        Effect of Programme A – Effect of Programme B 
 In ICER, the numerator (cost) is expressed as monetary unit and the denominator 
(effect) is expressed in appropriate health units which must be the same units between 
two interventions. For instance, life-years gained in CEA whereas QALY in CUA. 
Therefore, ICER may be expressed as cost per life-years gained or cost per QALY. 
ICER reflects the additional cost per unit of health benefits obtained in switching from 
one medical intervention to another. It compares medical interventions and provides 
information for resource allocation. When used in proper context, ICER serves as one of 
the vital tools in guiding decision making on allocating scarce resources across 
competing medical interventions (Bambha and Kim, 2004). 
 
1.3 Decision Making Using Cost-effectiveness Plane 
Cost-effectiveness (CE) plane is a two-dimensional graphical device used to illustrate 
the cost-effectiveness of two comparing alternatives (Black, 1990). CE plane is often 
used to show how decisions can be related to both costs and effects (Briggs and Fenn, 
1998). It is now a generally accepted method of presenting the results of CEA and CUA 
(Sendi and Briggs, 2001). The CE plane is shown in Figure 1.2. 
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Figure 1.2: The Cost-effectiveness Plane 
Source: Adapted from Briggs, 1998 
 
 
 In Figure 1.2, the horizontal axis represents the differences in effectiveness while 
the vertical axis represents the differences in cost. The CE plane is divided into four 
quadrants indicating four possible situations in relation to the additional costs and 
additional health outcome effects of a new intervention compared to the controlled 
intervention (the origin) (Briggs and Fenn, 1998). In CE plane, any intervention 
characterised by a certain cost and effectiveness may be represented by a point. A point 
will be allocated to the right side on the CE plane if an intervention is more effective and 
vice versa. Similarly, the more costly the intervention is, the higher the point will be 
seen on CE plane (Bambha and Kim, 2004).  
 If a new intervention is simultaneously cheaper and more effective than the other 
alternative, it will be plotted in quadrant II of CE plane. In this situation, new 
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intervention is clearly the treatment of choice because it is the most cost-effective and is 
said to dominate or sometimes it is called ‘dominant’. In contrast, the least cost-effective 
strategies fall on quadrant IV in which the intervention has an increased cost and 
decreased effectiveness compared to the alternative. In such a condition, the new 
intervention is dominated by the old intervention and should not be adopted. However, if 
a new intervention is both more costly and more effective (quadrant I), or less costly and 
less effective (quadrant III), then the decision is no longer clear. In this context, a 
judgement must be made concerning whether the difference in costs resulting from a 
switch in therapy is justified by the difference in effectiveness that such a switch would 
bring about (Briggs and Fenn, 1998, Bambha and Kim, 2004). 
 
1.3.1 What is Cost-effectiveness Threshold? 
ICER alone does not allow policymakers to judge whether a healthcare intervention 
represents good value for money. To draw conclusions on the CE of healthcare 
interventions, the derived ICER (from CEA and CUA) needs to be compared to a 
reference value, which is CE threshold value or sometimes it is also known as ICER 
threshold or ceiling threshold (Cleemput et al., 2008, Thavorncharoensap et al., 2013). 
The ceiling threshold can be represented by the dashed line on the CE plane in Figure 
1.2. Any intervention with calculated ICER appears above the CE threshold line would 
be deemed not cost-effective while it would be considered cost-effective if it falls below 
the line, indicating some monetary value of a QALY. Apparently, this CE threshold 
value serves as the maximum acceptable value for ICER (Briggs and Fenn, 1998). In 
other words, CE threshold value is a boundary for the last intervention that would still be 
financed from a given fixed budget (Cleemput et al., 2008). CE threshold also reflects 
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the opportunity cost, where it represents the additional cost that needs to be imposed to 
forgo one QALY worth of health through displacement (Claxton et al., 2013). 
 
1.4 Application of Cost-effectiveness Threshold in Economic Evaluation  
Economic evaluations (particularly CEA and CUA) have increasingly been used as an 
important tool to support efficient resource allocation especially in the resource-
constraint society in healthcare sector. Inevitably, application of thresholds for CE ratios 
are appeared as a tool for the reimbursement of pharmaceuticals or formulary listing 
(Eichler et al., 2004). 
 As mentioned before, CE threshold would serve as a marginal benchmark (the 
last chosen point) for any new medical intervention to be deemed cost-effective. With 
this, it means that if a new medical intervention has a lower cost per QALY value (or 
ICER) than this marginal benchmark, it is likely to be accepted by healthcare policy 
makers (Weinstein, 2008).  Taking an example of a study done by Freeman et al, they 
found that the ICER of high dose dabigatran compared with warfarin for stroke 
prevention in atrial fibrillation was USD 45,372 and concluded that high dose dabigatran 
was deemed to be more cost-effective compared to adjusted-dose warfarin, based on the 
CE threshold of USD 50,000 per QALY in the United States (Freeman et al., 2011). 
Apparently, as seen from this study, CE threshold expressed in the term of cost per 
QALY would serve as a robust tool in the cost-effectiveness decision making. 
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1.5 Problem Statement 
In real world, outcomes from economic evaluations alone are not sufficient to inform 
policymakers in decision making. It is unclear to what degree CE is used to guide 
coverage decision. CEA cannot be considered as a proper decision making tool because 
it would lack a systematic and universally recognisable decision criterion (Bobinac et al., 
2010). 
 Decision making is a complex process, where effectiveness and CE are not the 
only two of many considerations in making policy choices. No matter how explicit and 
openly the decisions are taken, it is somehow desirable to have a preference-based value 
that citizens place on the gains in health and life expectancy that can be achieved with 
the new medical interventions. In such circumstances, estimating a country specific CE 
threshold is necessary (Eichler et al., 2004, Ahlert et al., 2013).  
 A number of countries have explicitly stated their own threshold values such as 
the United Kingdom, Ireland and so on. In Malaysia, however, there is lack of an 
explicit Malaysian threshold value of QALY. Current practice on covering decisions of 
new healthcare technologies is made without a transparent decision criterion. In this 
situation, it will contribute to more room for arbitrariness and ‘ad hoc’ consideration in 
decision making process. This will affect the identification of true opportunity cost of a 
new medical intervention, which, in turn, will impose inefficiency and inconsistency in 
decision making, and ruin the sustainability of healthcare funding system (Eichler et al., 
2004, Donaldson et al., 2010). Therefore, establishing a Malaysian CE threshold 
expressed in the term of cost per QALY is vital as it evolves as a solid criterion in 
decision making process. 
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1.6 Study Objectives 
 
The general objective of this study was to determine a CE threshold value for healthcare 
interventions in Malaysia. Specifically, it was aimed to find out the amount of 
willingness-to-pay (WTP) for a QALY in Malaysian society and the factors that affect 
the amount of WTP for a QALY.  
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1 Cost-effectiveness  Threshold Used Globally  
For many years, clinical evidence is often the only evidence required for deciding 
funding of healthcare interventions or drugs reimbursement. However, many countries 
are now considering the cost of drug as part of the important criteria in decision making 
due to the finite resources available in healthcare sector (Barnieh et al., 2014). In 
conjunction with this, economic evaluations are adopted in the decision making process, 
where they assist in determining the relative value for money of the interventions 
(Donaldson et al., 2010).  
 Results of economic evaluations (especially CEA and CUA) are usually 
summarised in ICER. ICER represents the incremental cost per incremental outcome of 
one intervention compared to another. In this context, a commonly used measure of 
health outcome is QALY. By default, ICER is expressed as incremental cost per QALY 
gained (Bobinac et al., 2010).   
 To decide on the CE of medical interventions, external criterion in the form of 
CE threshold need to be applied to the ICER. Interpreting whether a derived ICER is 
acceptable requires the use of CE threshold (Claxton et al., 2013). Hence, the CE 
threshold, also presented as WTP/QALY gained value, is vital for decision making using 
economic evaluation. Johannesson and Meltzer, 1998, had argued the importance of 
explicating a threshold value. They claimed that without CE threshold, CEA cannot be 
considered a proper decision making tool because it would lack a systematic and 
universally recognisable decision criterion (Johannesson and Meltzer, 1998). 
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  In conjunction with this, three countries in Europe, namely the United Kingdom 
(England and Wales), Ireland and the Slovak Republic have explicitly stated a CE 
threshold each for funding or informing decision about listing a drug on formulary. 
(Barnieh et al., 2014). The National Institute for Health and Clinical Excellence (NICE) 
in the United Kingdom has set a threshold value of Great Britain Pound (GBP) 20,000 – 
30,000 per QALY gained for England and Wales, whereas Ireland’s threshold is Euro 
(EUR) 20,000 per QALY gained (Appleby et al., 2007, Shiroiwa et al., 2010, Barnieh et 
al., 2014). In the Slovak Republic, they use a threshold ranging from EUR 18,000 – 
26,500 per QALY for drug reimbursements (Barnieh et al., 2014). 
 The Netherlands, Sweden and France also apply threshold values in the practice, 
although these values are generally not explicitly acknowledged by the policymakers in 
these countries (Donaldson et al., 2010). In the United States, a threshold of United 
States Dollar (USD) 50,000 – 100,000 per QALY is widely used as a benchmark for 
assessing the CE of an intervention (Grosse, 2008, Shiroiwa et al., 2010). In addition, a 
threshold of Canadian Dollar (CAD) 20,000 – 100,000 was recommended in Canada 
since two decades ago (Laupacis et al., 1992). 
 Besides Western countries, Asia-Pacific countries like Australia, New Zealand 
and Japan have also mentioned CE threshold for the use in their countries, despite the 
fact that the values are arbitrary stated (Simoens, 2009, Shiroiwa et al., 2013). 
Nevertheless, as economic evidence is increasingly required in healthcare decision 
making, CE threshold plays an important role in the process.   
 In the recently done European value of a quality-adjusted life-year (EuroVaQ) 
study in Europe, it is clearly noted that CE threshold has become an indispensable tool 
in economic evaluation to have a more consistent and transparent decision making 
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process. Along with this, HTAsiaLink, a network of health technology assessment (HTA) 
organisations in Asia has embarked on first collaborative research on determining the 
CE threshold across 4 countries in Asia Pacific region namely Korea, Japan, Malaysia, 
and Thailand. Table 2.1 shows the summary of the CE threshold used in the public 
domain in some countries, although some are generally not explicitly acknowledged by 
the healthcare decision making body within each country. 
 
Table 2.1: Summary of the Currently Used Cost-effectiveness Thresholds 
Country CE Threshold in Local Currency Reference 
Australia AUD 42,000 – 76,000 per life year Simoens, 2009 
Canada CAD 20,000 – 100,000 per QALY Laupacis et al., 1992 
France EUR 50,000 per QALY Donaldson et al., 2010 
Ireland EUR 20,000 per QALY Barnieh et al., 2014 
Japan JPY 5 – 6 million per QALY Shiroiwa et al., 2013 
Netherlands EUR 20,000 per QALY Donaldson et al., 2010 
New Zealand NZD 3,000 – 15,000 per QALY PHARMAC, 2007 
Slovak Republic EUR 18,000 – 26,500 per QALY Barnieh et al., 2014 
Sweden SEK 400,000 – 655,000 per QALY Donaldson et al., 2010 
United Kingdom 
(England and Wales) 
GBP 20,000 – 30,000 per QALY Appleby et al., 2007 
United States USD 50,000 – 100,000 per QALY 
Grosse, 2008 & Shiroiwa 
et al., 2010 
Abbreviations: AUD, Australian Dollar; CAD, Canadian Dollar; EUR, Euro; JPY, 
Japanese Yen; NZD, New Zealand Dollar; SEK, Swedish Krona; GBP, Great Britain 
Pound; USD, United States Dollar; QALY, Quality-Adjusted Life-Year. 
 
2.2 Conceptual Tools in the Determination of Cost-effectiveness Threshold 
 
In view of the necessity to have CE threshold in decision making, various approaches 
have been used to define CE threshold, including league table approach, human capital 
approach and preference-elicitation approach (Shillcut et al., 2009). 
 In league table approach, the interventions are distributed in a table from the 
most to the least cost effective. Then, CE threshold is revealed as the CE ratio of the last 
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intervention to be approved as funds are exhausted. The drawback in this approach is the 
requirement to evaluate all the potential programmes to determine the last intervention 
in which this theoretical ideal is unachievable (Shillcut et al., 2009, Newall et al., 2014). 
 By defining a person’s life according to the average income of individuals within 
the society, a human capital approach is implied. In this approach, individuals are 
entitled to their ‘fare share’ of a nation’s wealth (Shillcut et al., 2009, Newall et al., 
2014). Defining CE threshold based on the economic activity of individuals is gaining 
recognition in economic evaluations in low- and middle-income countries (LMIC). The 
Commission for Macroeconomics and Health applied per capita income and the World 
Health Organisation (WHO) applied gross domestic product (GDP) initiated from World 
Health Organisation’s CHOosing Interventions that are Cost-Effective (WHO-CHOICE) 
project as their thresholds (Shillcut et al., 2009). In WHO-CHOICE threshold, 
interventions with CE ratio below the GDP per capita are deemed ‘very cost-effective’ 
and those with CE ratio below three times the per capita GDP are deemed ‘cost-effective’ 
(Newall et al., 2014). 
 The reference to the WHO-CHOICE threshold has been widely used for 
economic evaluation in LMIC (Newall et al., 2014). However, the acceptance of WHO-
recommended threshold value remains controversial because it depends on the 
robustness of the assumptions behind the estimation of the regional GDP per capita. The 
use of such a generalised threshold value may not be entirely relevant in every country, 
as different countries may have distinct socio-demographic and disease burdens despite 
having similar GDPs per capita. By using GDP per capita as an indicator, a nation’s 
average wealth does not necessarily indicate the state of wealth of every member of 
society. For example, the incomes of some individuals in rural areas may remain low, 
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although they live in high-income countries, and may not fairly represent a nation’s 
wealth (Decision Support Unit of National Institute for Health and Clinical Excellence., 
2007).  Moreover, the threshold values estimated in this human capital approach may not 
reflect the budget available or the preferences of society (Newall et al., 2014). 
 In preference-elicitation approach, CE thresholds are established either by the 
evaluation of real world decisions (revealed preference) or hypothetical scenarios (stated 
preference) of individuals within the society for the outcome of interest (Shillcut et al., 
2009, Newall et al., 2014). In this approach, the threshold values estimated may help 
inform on questions of how much to spend on health but may be of limited use where 
budget are constrained. Because the threshold are not linked to the available budget, 
their use can lead to continual growth in healthcare spending as more interventions 
emerge that meet the cost-effectiveness criteria (Birch and Gafni, 2006). To date, there 
is no accepted standard method to estimate the CE threshold value (Eichler et al., 2004). 
However, Thavorncharoensap et al. mentioned that the value of a QALY estimated in 
terms of a society’s WTP per QALY should be adopted as the ceiling threshold 
(Thavorncharoensap et al., 2013). Hence, in this study, preference-elicitation 
approached was chosen in the exploration of CE threshold. 
 The main outline in the determination of CE threshold is by eliciting the 
monetary value of a QALY. Estimating the value of a QALY is complicated and it 
involves some extent of methodological challenges. Due to the absence of typical ‘buy 
and sell’ transaction of a marketed good when placing a monetary value of a QALY, 
actual cost or sales information is seldom available. Having this situation, it is necessary 
to have an accurate valuation technique to elicit the economic value of a QALY that 
public places on it (Carson, 2000). 
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A variety of valuation techniques have been developed by economists to value 
non-marketed goods in consistent with the valuation of marketed goods. These valuation 
techniques are usually based on either revealed preference approach (observing 
behaviour toward some marketed goods in connection with the non-marketed goods of 
interest) or stated preference approach (using ‘stated’ information concerning 
preferences for non-marketed goods) (Carson, 2000, Carson and Hamemann, 2005).  
In environmental economics literatures, examples of revealed preference 
approach are hedonic pricing and the household production function approach while the 
stated preferences approach is frequently referred to contingent valuation (CV) (Carson 
and Hamemann, 2005). Hedonic pricing is a method used to estimate economic values 
for environmental services that directly affect market prices. The basis of this approach 
is that the price of a marketed good is related to its characteristics. Thus, valuation can 
be done by looking at how people are willing to pay for a good based on its 
characteristics (Vanslembrouck et al., 2005).  
In household production function approach, the households typically produce 
commodities through combining goods usually purchased in the market place with their 
own time. This approach is mainly focusing on the demand of commodities as functions 
of commodity prices, which, depend on goods prices and the household’s technology. 
As a basis, the price of a unit of commodity is the sum of prices of goods purchased and 
of the time used per unit of commodity. For instance, in the process of baking a bread, 
the price of the bread is the sum of the prices of flour, eggs, sugar purchased and of the 
time used to bake the bread (Becker, 1965, Pollak and Wachter, 1975).  
On the other hand, the contingent valuation method (CVM) is a survey method 
used to measure people’s WTP or willingness-to-accept (WTA) and is one of the most 
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widely used approaches developed for the measurement of the value of non-marketed 
goods through hypothetical survey questions (Johannesson and Jonsson, 1991, Food and 
Agriculture Organization Information Division, 2000). CVM is the most popular method 
used in recent years as it can cover wide range of themes such as measuring project 
benefits in monetary terms, or assessing social impacts of environmental conservation 
policies (Fujita et al., 2005).  
 
2.2.1 Contingent Valuation Method 
 
CV is a non-market valuation method used to estimate the value that a person places on 
a good using stated preference information (Food and Agriculture Organization 
Information Division, 2000, Hoyos and Mariel, 2010). This method is commonly used to 
elicit the individual’s preference for a non-marketed good where it measures directly a 
respondent’s WTP to obtain a specific good, or WTA to give up a good through the 
survey instrument (Arrow et al., 1993, Hoyos and Mariel, 2010).  
In CV, it creates a hypothetical marketplace for valuation of non-marketed goods 
in which no actual transactions are made. It has proven useful when implemented alone 
or jointly with other valuation technique for non-marketed goods (Food and Agriculture 
Organization Information Division, 2000). It remains as a technique capable of directly 
eliciting a monetary (Hicksian) measure of welfare (Hoyos and Mariel, 2010). 
 Using CVM, the values obtained are contingent on the information given. It 
means that the values are obtained from the respondents in a survey by using stated 
information concerning preferences for the good (Carson and Hamemann, 2005). In 
other words, CVM is a way of simulating a missing market where individual expresses 
his or her valuation for a good, contingent on a certain scenario (Berger et al., 2003).  
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CV surveys have been used to value a discrete change in the provision of an 
environmental good, the value associated with substituting one good for another, or the 
marginal substitution of different attributes of an existing good (Carson and Hamemann, 
2005, Hoyos and Mariel, 2010). Now, this technique has also been used for measuring 
the value of life, or the value of health improvements (Berger et al., 2003). 
 
2.2.1.1 Economic Theory of Contingent Valuation Method 
CV is deeply rooted in welfare economics, which is the study of well-being of members 
of a society as a group. In this context, the sum of social benefits requires the 
aggregation of individual’s benefits, and that an individual is the best judge of his or her 
own welfare (Berger et al., 2003, Hoyos and Mariel, 2010).  
CV applies surveys to measure an economic concept of value (Carson and 
Hamemann, 2005). To estimate an individual’s benefits, CV triggers the measurement of 
the net change in the income of an individual that relates to a change in the quality and 
quantity of a non-marketed good. In other words, it links the survey instrument and 
economic theory, where CV survey provides information to elicit the WTP (or WTA) 
distribution for a change in a good (Hoyos and Mariel, 2010). From the perspective of 
WTP, the maximum amount a person would be willing to offer for a good can be elicited. 
On the other hand, for WTA, the value attributed by CVM is evaluated by the minimum 
monetary amount required for an individual to forgo some good, or to bear some harm 
(Martin-Fernandez et al., 2010). 
The relationship between WTP and WTA is vital in CEA because the rules of 
decision are based on the acceptability of the incremental cost per unit of effectiveness. 
This could be interpreted to mean that this cost would be acceptable or not is depending 
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on the estimated societal WTP for an additional unit of health effect. A WTA/WTP ratio 
greater than one carries the meaning that the utility perceived by the loss is greater than 
that perceived by an equivalent gain. Consecutively, this has implications for the CE 
threshold at which to declare an intervention to be cost-effective, depending on whether 
it represents an increase in the utility with a cost increase (quadrant I of CE plane) or a 
loss of utility with lower costs (quadrant III of CE plane) (O'Brien et al., 2002, Martin-
Fernandez et al., 2010). 
 Besides, CV combines economic theory with the utility function. The utility 
theoretical model provides a basic framework for interpreting the responses to a CV 
study. As these responses are usually treated as random variables, the economic model 
needs to incorporate a stochastic component and the WTP/WTA distributions need to be 
linked to the survey response probability with the assumption that an individual 
maximises his or her utility (Hoyos and Mariel, 2010). In welfare economics, it seeks to 
reveal whether the potential change in utility resulting from a change in an economic 
variable. The welfare implications are usually expressed in terms of a change in an index 
(the monetary amount), which would need to be taken from or given to an individual to 
keep the individual’s overall level of utility constant (Carson et al., 2001). 
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2.2.1.2 Survey Design in Contingent Valuation Studies 
The design of questionnaire is a key aspect in CVM. To have a high quality CV study, 
the information described in the questionnaire should be consistent with scientific and 
expert knowledge. The hypothetical scenario constructed has to be as closely as possible 
to the real-world situation. In addition, the description of the good under valuation 
should be understandable and comprehensible to a respondent who might know little or 
nothing about the good. In CV study, face validity is considered as a desired property, 
where the information provided in the survey instrument should be clear and accurate, 
and the trade-off that the respondent is asked to make should be plausible in order to 
make a decision (Carson and Hamemann, 2005, Hoyos and Mariel, 2010). 
 In most of the CV surveys, the questionnaires are normally designed with general 
(“warm-up”) questions introducing the purpose of the survey in opening session to make 
the respondents comfortable with participating in the survey. In second section, a clear 
and detailed description of the CV scenario and the good to be valued should be 
provided. This includes the current and baseline situation (status quo) and possible 
future states of the natural resource in the case of no implementation of the proposed 
policy, including the institutional context in which the good will be provided and the 
payment vehicle. Accompanying materials such as charts or photographs may be used to 
aid with the description of the scenario (Food and Agriculture Organization Information 
Division, 2000, Carson and Hamemann, 2005). 
 This is followed by elicitation section or payment question, which queries 
respondents about their maximum WTP for a commodity or the minimum WTA for 
giving it up. The next section is the analysis of the understanding and certainty of the 
answer provided by the respondents. In the last section, a set of questions regarding the 
